Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
暂无分享,去创建一个
F. Puglisi | G. Romieu | G. von Minckwitz | I. Láng | M. De Laurentiis | J. Gligorov | J. Cortés | C. Zielinski | E. Vrdoljak | C. Villanueva | E. Ciruelos | C. Veyret | U. Freudensprung | N. Marschner | S. Srock | S. de Ducla